2024-513006-61-00RecruitingPhase 1
An open-label, multicentre, rollover study to evaluate safety and antineoplastic activity of OATD-02 in patients with selected advances and/or metastatic solid tumours who completed the first-in-human study OATD-02-C-01
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Feb 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 10 Apr 2024
- Start date
- 23 Aug 2023
- Lead sponsor
- Molecure S.A.
- EU CT number
- 2024-513006-61-00
- EudraCT number
- 2022-003806-61
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 30
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy | Bydgoszcz | Poland | Recruiting |
| Europejskie Centrum Zdrowia Otwock Sp. Z.o.o. | Otwock | Poland | Recruiting |
| LUX MED Onkologia Sp. z.o.o. | Warsaw | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.